Daiwa Securities Group Inc. Acquires New Position in Gritstone bio, Inc. (NASDAQ:GRTS)

Daiwa Securities Group Inc. acquired a new stake in Gritstone bio, Inc. (NASDAQ:GRTSGet Rating) during the 4th quarter, Holdings Channel.com reports. The firm acquired 7,655 shares of the company’s stock, valued at approximately $98,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Denali Advisors LLC acquired a new position in Gritstone bio in the fourth quarter valued at approximately $59,000. Citigroup Inc. lifted its holdings in Gritstone bio by 57.6% in the third quarter. Citigroup Inc. now owns 4,603 shares of the company’s stock valued at $50,000 after buying an additional 1,682 shares during the period. FNY Investment Advisers LLC acquired a new position in Gritstone bio in the fourth quarter valued at approximately $91,000. Hershey Trust Co. acquired a new position in Gritstone bio in the third quarter valued at approximately $95,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in Gritstone bio by 59.1% in the third quarter. BNP Paribas Arbitrage SA now owns 9,071 shares of the company’s stock valued at $98,000 after buying an additional 3,370 shares during the period. Institutional investors and hedge funds own 69.92% of the company’s stock.

Shares of NASDAQ:GRTS opened at $3.06 on Friday. Gritstone bio, Inc. has a 52 week low of $3.02 and a 52 week high of $14.42. The company has a market capitalization of $222.49 million, a PE ratio of -3.22 and a beta of 0.36. The company has a 50 day moving average price of $4.38 and a two-hundred day moving average price of $7.68.

Gritstone bio (NASDAQ:GRTSGet Rating) last issued its earnings results on Thursday, March 10th. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.01. Gritstone bio had a negative net margin of 155.73% and a negative return on equity of 37.44%. As a group, equities analysts forecast that Gritstone bio, Inc. will post -1.49 earnings per share for the current year.

Separately, HC Wainwright lowered their target price on shares of Gritstone bio from $24.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, March 14th.

Gritstone bio Company Profile (Get Rating)

Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.

Featured Stories

Want to see what other hedge funds are holding GRTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gritstone bio, Inc. (NASDAQ:GRTSGet Rating).

Institutional Ownership by Quarter for Gritstone bio (NASDAQ:GRTS)

Receive News & Ratings for Gritstone bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone bio and related companies with MarketBeat.com's FREE daily email newsletter.